Equities research analysts at Cantor Fitzgerald increased their FY2024 earnings estimates for PTC Therapeutics in a report ...

William Blair increased their FY2024 earnings estimates for PTC Therapeutics in a report issued on Monday, January 13th.

Cantor Fitzgerald lowered the firm’s price target on PTC Therapeutics (PTCT) to $76 from $80 and keeps an Overweight rating on the shares. The ...

Leerink Partners analyst Joseph Schwartz has maintained their neutral stance on PTCT stock, giving a Hold rating yesterday.Stay Ahead of the ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 3, 2025, the company approved 1,200 restricted stock units ("RSUs"), each representing the right to receive one share of its common ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2025. Matthew B. Klein, M.D., Chief Executive Officer of PTC, will discuss these updates at ...

Gabrielle White has been appointed as president of the Irish Exporters Association, the organisation said on Thursday. She ...

PTC Therapeutics (NASDAQ:PTCT) said a Phase 2 placebo-controlled study of its ALS drug candidate utreloxastat failed to meet its primary and secondary efficacy endpoints.The biotech company said ...

2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the vatiquinone New Drug Application (NDA) for the treatment of children and adults living with ...

WARREN, N.J., Jan. 13, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 3, 2025, the company approved 1,200 restricted stock units ("RSUs"), each representing ...